Wanna Get Away? Maintenance Treatments and Chemotherapy Holidays in Gynecologic Cancers.

View/ Open
Date
2019-01ICR Author
Author
Madariaga, A
Rustin, GJS
Buckanovich, RJ
Trent, JC
Oza, AM
Type
Journal Article
Metadata
Show full item recordAbstract
Epithelial ovarian cancer has a very high rate of relapse after primary therapy; historically approximately 70% of patients with a complete clinical response to surgery and adjuvant chemotherapy will relapse and die of the disease. Although this number has slowly improved, cure rates remain less than 50%. As such, maintenance therapy with the aim of preventing or delaying disease relapse and the goal of improving overall survival has been the subject of intense study. Numerous earlier studies with agents ranging from radioactive phosphorus to extended frontline therapy or to monthly taxol administration demonstrated encouraging improvements in progression-free survival (PFS) only to find, disappointingly, no benefit in overall survival. In addition, the PFS advantage of maintenance therapy was associated with disconcerting side effects such that maintenance therapy was not adapted as standard of care. Studies with bevacizumab and PARP inhibitors have demonstrated a PFS advantage with a manageable side-effect profile. However, an overall survival advantage remains unclear, and the use of these approaches thus remains controversial. Furthermore, in recurrent disease, the length of chemotherapy and benefits of extended chemotherapy is unclear. Thus, additional trials assessing maintenance strategies in ovarian and other gynecologic malignancies are needed.
Collections
Subject
Humans
Genital Neoplasms, Female
Recurrence
Antineoplastic Combined Chemotherapy Protocols
Treatment Outcome
Chemotherapy, Adjuvant
Drug Resistance, Neoplasm
Research Design
Female
Clinical Trials as Topic
Molecular Targeted Therapy
Consolidation Chemotherapy
Maintenance Chemotherapy
Biomarkers, Tumor
Language
eng
License start date
2019-01
Citation
American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting, 2019, 39 pp. e152 - e166
Except where otherwise noted, this item's license is described
as
https://creativecommons.org/licenses/by/4.0
Related items
Showing items related by title, author, creator and subject.
-
Outcomes following front-line chemotherapy in peripheral T-cell lymphoma: 10-year experience at The Royal Marsden and The Christie Hospital.
Gleeson, M; Peckitt, C; Cunningham, D; Gibb, A; Hawkes, EA; et al. (2018-07)We evaluated the outcomes for patients with peripheral T-cell lymphoma (PTCL) undergoing front-line chemotherapy at our institutions between 2002 and 2012. One hundred and fifty-six patients were eligible, comprising PTCL ... -
Hyperthermic intraperitoneal chemotherapy (HIPEC) as another treatment modality for desmoplastic round cell tumour patients: first paediatric experience from UK.
Sjoberg Bexelius, T; Chisholm, JC; Okoye, B; Cecil, T; Angelini, P; et al. (BMJ PUBLISHING GROUP, 2021-01-28)We present the first young paediatric patient with desmoplastic small round cell tumour (DSRCT) treated in UK with hyperthermic intraperitoneal chemotherapy (HIPEC). A 7-year-old girl was diagnosed with abdominal DSRCT ... -
Open-label, multicentre, randomised, phase II study of the EpSSG and the ITCC evaluating the addition of bevacizumab to chemotherapy in childhood and adolescent patients with metastatic soft tissue sarcoma (the BERNIE study).
Chisholm, JC; Merks, JHM; Casanova, M; Bisogno, G; Orbach, D; et al. (2017-09)Purpose We evaluated the role of bevacizumab as part of the multi-modality treatment of children and adolescents with metastatic rhabdomyosarcoma (RMS) or non-rhabdomyosarcoma soft tissue sarcoma (NRSTS).Patients and methods ...